Navigation Links
Advanced Instruments Signs License and Sensor Development Agreement With Cantimer, Inc.
Date:2/23/2010

ents. "The industry has been asking for this capability for many years and we believe Cantimer's technology will allow us to finally address their needs" he added.

Cantimer's sensor platform can be adapted to detect and measure a broad array of chemical and biological compounds of interest and has application in markets as large and diverse as life science research, point-of-care diagnostics, consumer health, bio-defense and environmental monitoring. The Company's technology enables the development of simple, portable devices that are robust, sensitive, low-cost, label-free and easy-to-use. In parallel to the development of its own first commercial product, a pocket device for non-invasive measurement and monitoring of changes in human hydration, the Company has undertaken a number of sensor development projects for strategic partners.

"Advanced Instruments has been a very supportive investor and an enthusiastic strategic partner", commented Robin Stracey, CEO of Cantimer, Inc. "We look forward to this joint development effort with great enthusiasm".

About Cantimer, Inc.

Cantimer is a priv
'/>"/>

SOURCE Cantimer, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
2. Advanced Life Sciences Previews 2010 Milestones
3. EPA Reaffirms Sugarcane Biofuel is Advanced Renewable Fuel with 61% Less Emissions than Gasoline
4. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
5. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
6. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
7. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
8. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
9. Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures
10. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
11. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... national nonprofit organization solely dedicated to finding a cure ... for those affected worldwide, will host its annual Crystal ... in Warrington, Pa. , Each year, the Crystal ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... has initiated coverage of Alliqua, Inc. (OTCQB: ALQA). ... manufacturing, and marketing proprietary products to serve the ... http://equitiesiq.com/reports/alliqua/ , In late 2012, Alliqua was ... which launched the company’s new strategy to become ...
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation ... discovering, developing and commercializing innovative therapies addressing ... today announced that it received the Notice ... and Trademark Office on its unique self-delivering ... fibrosis. The patent covers the use of ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 During the ... is now known as “The Doctor’s Plague.” In this ... to wash their hands. This led, at times, to ... medical interns and hospital staff today don’t know that ... patients. The CBCD explains. , A study showed that ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... 23, 2011 Novavax, Inc. (Nasdaq: NVAX ) ... results in a press release to be issued after 8:00 ... hold an investor conference call at 10:00 a.m. The call ... Dr. Rahul Singhvi and other members of senior management. The ...
... SA , a Swiss-based biotechnology company with technologies for ... stable mammalian cell lines for therapeutic ... sequencing of their proprietary Chinese hamster ovary (CHO) cell ... performed in collaboration with the Institute of Biotechnology ...
... MARLBOROUGH, Mass., March 23, 2011 Advanced Cell Technology, ... a leader in the field of regenerative medicine, announced ... allowed the Company,s patent application to provide broad intellectual ... preparations of retinal pigment epithelial (RPE) cells from human ...
Cached Biology Technology:Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 2Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 3Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 4ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 2ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 3
(Date:4/15/2014)... Center in Greenbelt, Md., is home to hundreds ... At Goddard, some of the most cutting-edge Earth ... of that cutting-edge innovation has earned a Goddard ... Society for Anthropology and Geography awards the Vega ... has shown excellence in the fields of physical ...
(Date:4/15/2014)... study of nearly 1,000 mother-child pairs, researchers from ... prenatal exposure to selective serotonin reuptake inhibitors (SSRIs), ... other disorders, was associated with autism spectrum disorder ... study, published in the online edition of ... ASD and DD cases, and population-based controls, where ...
(Date:4/15/2014)... University of Missouri researchers have previously shown that a ... exercise exists. In a new study, Frank Booth, a ... found a potential link between the genetic pre-disposition for ... which mental maturation occurs. , For his study, Booth ... activity or extreme laziness. Booth then put the rats ...
Breaking Biology News(10 mins):Goddard scientist receives Vega Medal from King of Sweden 2Study: SSRI use during pregnancy associated with autism and developmental delays in boys 2Genetic pre-disposition toward exercise and mental development may be linked 2
... (Jan. 28, 2009) Virginia Commonwealth University researchers have ... in regulating mitochondria, the energy-producing machines of cells. This ... new treatments for heart disease to boost energy in ... of cancer. In the study, published online Jan. ...
... available in French . MONTREAL, ... to announce that Concordia,s Centre for Structural and Functional ... by nine universities which are part of the Cellulosic ... the conversion of agricultural waste into biofuel is being ...
... This release is available in German . ... year as a result of pneumococcal infection, which causes ... and the elderly are especially at risk. Vaccines are ... and increasing resistance to antibiotics is making treatment more ...
Cached Biology News:Deceiving cell walls 2
... analysis kit for 10 chips provides the ... analysis with the Experion automated electrophoresis system. ... 3 x 520 microliters Pro260 gel, 45 ... (10-260 kD), 400 microliters Pro260 sample buffer, ...
... original Gene Pulser apparatus and accessory modules the ... in the Gene Pulser II system, which features ... Gene Pulser II system has the dual advantages ... range of settings to target specific cell types ...
Experion Pro260 chips are the microfluidic chips used to perform protein analysis with the Experion automated electrophoresis system. Each chip has the capacity to run 10 protein samples. Supplied as...
... Pro260 reagents and supplies, for 10 ... sufficient to perform protein analysis with ... electrophoresis system. Supplied are 3 x ... Pro260 stain, 60 microliters Pro260 ladder ...
Biology Products: